Risk Adapted Ablative Radiotherapy After Intensive Chemotherapy for Locally Advanced Pancreatic Cancer.
SAbR
SBRT (stereotactic body radiation therapy)
ablative dose
hypofractionated ablative radiation
locally advanced
pancreatic cancer
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
31
01
2021
accepted:
16
03
2021
entrez:
7
5
2021
pubmed:
8
5
2021
medline:
8
5
2021
Statut:
epublish
Résumé
To assess the efficacy of a Risk-Adapted Ablative Radiotherapy (RAdAR) approach, after intensive induction chemotherapy, in patients with locally advanced pancreatic cancer (LAPC). Patients with LAPC who received RAdAR following induction chemotherapy from January 2017 to December 2019 were included in this observational study. The RAdAR approach consisted of an anatomy- and simultaneous integrated boost (SIB)-based dose prescription strategy. RAdAR was delivered with stereotactic ablative radiation therapy (SAbR), administering 30 Gy in 5 fractions to the tumor volume (PTV Sixty-four LAPC patients were included. The RAdAR approach, following intensive induction chemotherapy, is an effective radiation treatment strategy for selected LAPC patients, representing a promising therapeutic option in a multimodality treatment regimen.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
To assess the efficacy of a Risk-Adapted Ablative Radiotherapy (RAdAR) approach, after intensive induction chemotherapy, in patients with locally advanced pancreatic cancer (LAPC).
MATERIAL AND METHODS
METHODS
Patients with LAPC who received RAdAR following induction chemotherapy from January 2017 to December 2019 were included in this observational study. The RAdAR approach consisted of an anatomy- and simultaneous integrated boost (SIB)-based dose prescription strategy. RAdAR was delivered with stereotactic ablative radiation therapy (SAbR), administering 30 Gy in 5 fractions to the tumor volume (PTV
RESULTS
RESULTS
Sixty-four LAPC patients were included.
CONCLUSIONS
CONCLUSIONS
The RAdAR approach, following intensive induction chemotherapy, is an effective radiation treatment strategy for selected LAPC patients, representing a promising therapeutic option in a multimodality treatment regimen.
Identifiants
pubmed: 33959509
doi: 10.3389/fonc.2021.662205
pmc: PMC8093383
doi:
Types de publication
Journal Article
Langues
eng
Pagination
662205Informations de copyright
Copyright © 2021 Rossi, Simoni, Paiella, Rossi, Venezia, Micera, Malleo, Salvia, Giuliani, Di Gioia, Auriemma, Milella, Guariglia, Cavedon, Bassi and Mazzarotto.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Clin Oncol. 1985 Mar;3(3):373-8
pubmed: 3973648
J Clin Oncol. 2011 Aug 1;29(22):3037-43
pubmed: 21709185
Cancer. 2020 May 15;126(10):2120-2131
pubmed: 32125712
Strahlenther Onkol. 2016 Dec;192(12):886-894
pubmed: 27757502
Cancer. 2017 Sep 15;123(18):3486-3493
pubmed: 28493288
Cancers (Basel). 2020 Jun 29;12(7):
pubmed: 32610592
Ann Oncol. 2017 Nov 1;28(11):2786-2792
pubmed: 28945895
Adv Radiat Oncol. 2020 Jun 25;6(1):100506
pubmed: 33665480
J Natl Cancer Inst. 1988 Jul 20;80(10):751-5
pubmed: 2898536
J Gastrointest Oncol. 2020 Dec;11(6):1399-1407
pubmed: 33457009
Int J Radiat Oncol Biol Phys. 2021 May 1;110(1):206-216
pubmed: 33358561
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Clin Oncol. 2009 Apr 10;27(11):1806-13
pubmed: 19273710
Lancet. 2016 Jul 2;388(10039):73-85
pubmed: 26830752
Cancer Med. 2019 May;8(5):2123-2132
pubmed: 30932367
JAMA Oncol. 2019 Jul 1;5(7):1020-1027
pubmed: 31145418
J Clin Oncol. 2007 May 20;25(15):1960-6
pubmed: 17452677
Anticancer Res. 2020 Jan;40(1):465-472
pubmed: 31892602
Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):755-65
pubmed: 26972648
Ann Surg. 2019 Aug;270(2):340-347
pubmed: 29596120
JAMA. 2016 May 3;315(17):1844-53
pubmed: 27139057
J Clin Oncol. 2011 Nov 1;29(31):4105-12
pubmed: 21969502
JAMA Surg. 2019 Oct 1;154(10):932-942
pubmed: 31339530
Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):516-22
pubmed: 23562768
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):1000-6
pubmed: 24267968
Acta Oncol. 2015 Jul;54(7):979-85
pubmed: 25734581
J Clin Oncol. 2016 Aug 1;34(22):2654-68
pubmed: 27247216
Lancet Oncol. 2016 Jun;17(6):801-810
pubmed: 27160474
Radiother Oncol. 2020 Nov;152:63-69
pubmed: 32763253
Radiat Oncol. 2019 Jun 6;14(1):95
pubmed: 31171025
J Radiat Res. 2016 Aug;57 Suppl 1:i53-i57
pubmed: 27029741
Clin Oncol (R Coll Radiol). 2021 Jan;33(1):e31-e38
pubmed: 32682686
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Front Oncol. 2020 Dec 17;10:600940
pubmed: 33392093